Ingo K. Mellinghoff
英格·梅林霍夫
MD
Chair, Department of Neurology; Head, Brain Tumor Center神经内科主任、脑肿瘤中心负责人
👥Biography 个人简介
Ingo Mellinghoff chairs Neurology at MSKCC and is the world's foremost expert on IDH inhibitor therapy for glioma. He led the INDIGO trial demonstrating vorasidenib's significant PFS benefit in IDH-mutant grade 2 glioma, marking a breakthrough in molecularly targeted CNS tumor therapy.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
IDH Inhibitor Development
Led preclinical and clinical development of IDH1/2 inhibitors in glioma, from ivosidenib to vorasidenib, establishing proof-of-concept for targeted therapy.
INDIGO Trial
Led the pivotal INDIGO phase III trial showing vorasidenib significantly extended PFS in IDH-mutant grade 2 glioma vs placebo.
CNS Drug Penetration
Advanced understanding of brain-penetrant IDH inhibitor pharmacology, optimizing CNS exposure for effective glioma treatment.
Representative Works 代表性著作
Vorasidenib in IDH1- or IDH2-mutant low-grade glioma (INDIGO trial)
New England Journal of Medicine (2023)
Phase III trial demonstrating vorasidenib reduced risk of progression or death by 61% in IDH-mutant grade 2 glioma.
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
New England Journal of Medicine (2005)
Identified PTEN loss and EGFRvIII co-expression as resistance determinants to EGFR inhibitors in GBM.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Timothy Cloughesy
UCLA Health / David Geffen School of Medicine
Patrick Y. Wen
Dana-Farber Cancer Institute / Harvard Medical School
Michael Weller
University Hospital Zurich / University of Zurich
Susan M. Chang
University of California San Francisco (UCSF)
关注 英格·梅林霍夫 的研究动态
Follow Ingo K. Mellinghoff's research updates
留下邮箱，当我们发布与 Ingo K. Mellinghoff（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment